There has been an explosion of new data from targeted therapy studies since the 2017 publication of ASCO’s full clinical practice guidelines regarding systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC). In light of these important updates, the panel of experts responsible for the 2017 guidelines reconvened to create a 2020 update exclusively focused on patients with stage IV NSCLC without driver alterations. Panel co-chair Nasser H. Hanna, MD, the Tom and Julie Wood Family Foundation professor of Lung Cancer Clinical Research at Indiana University School of Medicine, discussed the new guidelines update in an interview with MedPage Today.

Read the full interview transcript by clicking here.